natgillin/translations-raw huggingface dataset:
The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing ispaghula seed.
Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenja za promet z zdravili rastlinskega izvora, ki vsebujejo seme jajčastega trpotca.
Ispaghula seed should be taken with plenty of liquid.
Seme jajčastega trpotca je treba zaužiti z veliko tekočine.
Any applications for the licensing of medicines containing ispaghula seed have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Vlogo za izdajo dovoljenja za promet z zdravili, ki vsebujejo seme jajčastega trpotca, je treba predložiti pristojnemu nacionalnemu organu za zdravila, ki bo to vlogo za izdajo dovoljenja za promet z zdravilom rastlinskega izvora ocenil in upošteval znanstvene zaključke odbora HMPC.
The HMPC recommended that ispaghula seed should not be used in patients with a sudden change in bowel habit that persists for more than two weeks, and in patients with undiagnosed bleeding of the rectum and failure to pass stools following the use of a laxative.
Odbor HMPC je priporočil, da se seme jajčastega trpotca ne sme uporabljati pri bolnikih z nenadno spremembo pri odvajanju blata, ki traja več kot dva tedna, in bolnikih z nediagnosticirano krvavitvijo iz rektuma (danke) ter neuspešnim odvajanjem blata po uporabi odvajal.
Further information on the HMPC assessment of ispaghula seed medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Dodatne informacije o oceni zdravil, ki vsebujejo seme jajčastega trpotca, ki jo je opravil odbor HMPC, vključno z njegovimi znanstvenimi zaključki, so na voljo na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
The HMPC concluded that ispaghula seed can be used for the treatment of habitual constipation (constipation not caused by a physical change to an organ) and in conditions where softening of the stools is desirable to reduce pain when they are passed, such as anal fissures, haemorrhoids and after surgery to the anus or rectum.
Odbor HMPC je zaključil, da se lahko seme jajčastega trpotca uporablja za zdravljenje habitualne (ponavljajoče) zaprtosti (zaprtost, ki ni posledica organskih sprememb) in pri stanjih, ko je želeno omehčanje blata, da se zmanjša bolečine pri njegovem odvajanju, na primer pri analnih fisurah (zadnjičnih razpokah), hemoroidih (zlati žili) in po kirurškem posegu na anusu (zadnjiku) ali rektumu (danki).
How are ispaghula seed medicines approved in the EU?
Kako so zdravila, ki vsebujejo seme jajčastega trpotca, odobrena v EU?
Detailed instruction on how to take ispaghula seed medicines and who can use them can be found in the package leaflet that comes with the medicine.
Podrobna navodila o jemanju zdravil s semenom jajčastega trpotca in o te, kdo jih lahko jemlje, so na voljo v navodilu za uporabo, ki je priloženo posameznemu zdravilu.
Ispaghula seed contains dietary fibre which when mixed with water forms a gel-like mass that works as a mild laxative (medicine used to treat constipation).
Seme jajčastega trpotca vsebuje prehranske vlaknine, ki pomešane z vodo tvorijo gelu podobno zmes, ki deluje kot blago odvajalo (zdravilo za zdravljenje zaprtosti).
Ispaghula husk has been studied in over 900 patients showing effectiveness as a mild laxative.
Lupino semena jajčastega trpotca so preučevali pri več kot 900 bolnikih in ugotovili, da učinkuje kot blago odvajalo.
What is ispaghula seed?
Kaj je seme jajčastega trpotca?
Herbal medicines containing ispaghula seed are usually available in solid forms to be taken by mouth.
Zdravila rastlinskega izvora, ki vsebujejo seme jajčastega trpotca, so navadno na voljo v trdnih oblikah, ki se jemljejo peroralno (zaužijejo skozi usta).
Other information about ispaghula seed medicines
Druge informacije o zdravilih, ki vsebujejo seme jajčastega trpotca
Ispaghula seed is used in the form of whole, dried, seeds or as preparations obtained by powdering the seeds.
Seme jajčastega trpotca se uporablja kot celo posušeno seme ali v obliki pripravkov, izdelanih z drobljenjem semen v prašek.
What are the risks associated with ispaghula seed medicines?
Kakšna tveganja so povezana z zdravili, ki vsebujejo seme jajčastega trpotca?
For practical information about using ispaghula seed medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravil s semenom jajčastega trpotca naj bolniki preberejo navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujejo z zdravnikom ali farmacevtom.
What evidence supports the use of ispaghula seed medicines?
Kateri dokazi podpirajo uporabo zdravil, ki vsebujejo seme jajčastega trpotca?
Side effects have been reported with ispaghula seed medicines, including flatulence and abdominal distension (swelling of the belly).
Pri zdravilih, ki vsebujejo seme jajčastega trpotca, so poročali o neželenih učinkih, vključno s flatulenco (nabiranje plinov v želodcu in črevesju, vetrovi) in abdominalno distenzijo (napihnjenostjo trebuha) .
For more information about treatment with ispaghula seed medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravili, ki vsebujejo seme jajčastega trpotca, preberite navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujte z zdravnikom ali farmacevtom.
Ispaghula seed
Seme jajčastega trpotca
At the same time ispaghula seed lubricates the intestine which improves the transit of stools.
Seme jajčastega trpotca obenem podmaže črevo, s čimer se izboljša prehajanje blata.
The data on ispaghula husk support therefore the use of ispaghula seed as a laxative.The effectiveness of ispaghula seed in softening stools is based on its laxative effects and no specific data are available.
Učinkovitost semena jajčastega trpotca pri mehčanju blata temelji na njegovih odvajalnih učinkih, posebnih podatkov pa ni na voljo.
The exact way in which levetiracetam works is still unclear but it attaches to a protein called synaptic vesicle protein 2A, which is involved in the release of chemical messengers from nerve cells.
Natančen način delovanja levetiracetama še vedno ni pojasnjen, znano pa je, da se pritrdi na beljakovino, imenovano sinaptični vezikularni protein 2A, ki sodeluje pri sproščanju kemičnih prenašalcev iz živčnih celic.
What measures are being taken to ensure the safe and effective use of Levetiracetam Teva?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Levetiracetam Teva?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Levetiracetam Teva have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo zdravstveni delavci in bolniki upoštevati za varno in učinkovito uporabo zdravila, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
For more information about treatment with Levetiracetam Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Levetiracetam Teva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
• partial-onset seizures with or without generalisation in patients from 1 month of age;
• napadov parcialnega izvora z generalizacijo ali brez nje pri bolnikih, starejših od enega meseca;
The European Commission granted a marketing authorisation valid throughout the European Union for Levetiracetam Teva on 26 August 2011.
Evropska komisija je dovoljenje za promet z zdravilom Levetiracetam Teva, veljavno po vsej Evropski uniji, izdala 26. avgusta 2011.
This means that Levetiracetam Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Keppra.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Keppra.
What are the benefits and risks of Levetiracetam Teva?
Kakšne so koristi in tveganja, povezani z zdravilom Levetiracetam Teva?
Other information about Levetiracetam Teva
Druge informacije o zdravilu Levetiracetam Teva
This is a summary of the European public assessment report (EPAR) for Levetiracetam Teva.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Levetiracetam Teva.
Levetiracetam Teva is a ‘generic medicine'.
Levetiracetam Teva je „generično zdravilo“.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levetiracetam Teva.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Levetiracetam Teva, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Patients unable to swallow should be given a solution containing levetiracetam.
Bolniki, ki ne morejo požirati, morajo prejemati raztopino z levetiracetamom.
Because Levetiracetam Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Levetiracetam Teva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
This helps Levetiracetam Teva to stabilise electrical activity in the brain and prevent seizures.
Taki zdravilo Levetiracetam Teva stabilizira električno dejavnost v možganih in prepreči napade.
The full EPAR for Levetiracetam Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Levetiracetam Teva can also be used as an add-on to other epilepsy medicines to treat:
Zdravilo Levetiracetam Teva se lahko uporablja kot dodatek drugim zdravilom proti epilepsiji za zdravljenje:
When Levetiracetam Teva is added to another epilepsy treatment, the starting dose in patients over 12 years weighing more than 50 kg is 500 mg twice a day.
Kadar se zdravilo Levetiracetam Teva dodaja drugemu zdravilu proti epilepsiji, je začetni odmerek pri bolnikih, starejših od 12 let, ki tehtajo več kot 50 kg, 500 mg dvakrat dnevno.
Therefore, the CHMP's view was that, as for Keppra, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Keppra, odtehtajo znana tveganja.
Levetiracetam Teva tablets are swallowed with liquid.
Tablete Levetiracetam Teva je treba pogoltniti s tekočino.
Levetiracetam Teva can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation.
Zdravilo Levetiracetam Teva se lahko uporablja kot samostojno zdravilo pri bolnikih, starejših od 16 let, ki so jim na novo diagnosticirali epilepsijo, za zdravljenje napadov parcialnega izvora s sekundarno generalizacijo ali brez nje.
The CHMP concluded that, in accordance with EU requirements, Levetiracetam Teva has been shown to have comparable quality and to be bioequivalent to Keppra.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Levetiracetam Teva primerljivo raven kakovosti kot zdravilo Keppra ter da mu je biološko enakovredno.
Because Levetiracetam Teva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Keppra.
Ker je zdravilo Levetiracetam Teva generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Keppra.
The Committee recommended that Levetiracetam Teva be given marketing authorisation.
Priporočil je, da se za zdravilo Levetiracetam Teva izda dovoljenje za promet.
The active substance in Levetiracetam Teva, levetiracetam, is an epilepsy medicine.
Zdravilna učinkovina zdravila Levetiracetam Teva, levetiracetam, je zdravilo za zdravljenje epilepsije.
Levetiracetam Teva is a medicine that contains the active substance levetiracetam.
Levetiracetam Teva je zdravilo, ki vsebuje zdravilno učinkovino levetiracetam.
Why has Levetiracetam Teva been approved?
Zakaj je bilo zdravilo Levetiracetam Teva odobreno?
The dose can be further increased at two-week intervals according to the patient's response, to a maximum dose of 1,500 mg twice a day.
Odmerki se lahko glede na bolnikov odziv še naprej povečujejo v dvotedenskih razmakih do največjega odmerka 1 500 mg dvakrat dnevno.
When Levetiracetam Teva is used on its own, the starting dose is 250 mg twice a day, increasing two weeks later to 500 mg twice a day.
Začetni samostojni odmerek zdravila Levetiracetam Teva je 250 mg dvakrat dnevno, po dveh tednih jemanja pa se poveča na 500 mg dvakrat dnevno.
How has Levetiracetam Teva been studied?
Kako je bilo zdravilo Levetiracetam Teva raziskano?
What is Levetiracetam Teva?
Kaj je zdravilo Levetiracetam Teva?
What is Levetiracetam Teva used for?
Za kaj se zdravilo Levetiracetam Teva uporablja?
How is Levetiracetam Teva used?
Kako se zdravilo Levetiracetam Teva uporablja?
How does Levetiracetam Teva work?
Kako zdravilo Levetiracetam Teva deluje?
100 capsules
100 kapsul
200 mg Capsule, hard
200 mg kapsula, trda peroralna uporaba steklenička (stekla)
The potential risk for humans is unknown.
Možnost tveganja za ljudi ni znano.
These trials are briefly described below.
Na kratko sta opisani spodaj.
Date of first authorisation: 11th January 2016
Datum prve odobritve: 11th Januar 2016
Monitoring of laboratory values
Spremljanje laboratorijskih vrednosti
The undesirable effects are listed by body system and frequency.
Neželeni učinki so navedeni po organskih sistemih in pogostnosti.
Take care to ensure that only the anterior wall of the femoral artery is punctured.
Pazite, da boste prebodli le sprednjo steno femoralne arterije.
EARLY-ACS trial
Študija EARLY-ACS
Wessling Hungary Kft Fòti ùt 56, Budapest 1047, Hungary
Wessling Hungary Kft Fòti ùt 56, Budapest 1047, Madžarska
Tell your doctor if you are pregnant, think you might be pregnant or are planning to have a baby.
Zdravniku morate povedati, če ste noseči ali mislite, da bi lahko bili noseči ali načrtujete zanositev.
This recommendation is based on pharmacodynamic and pharmacokinetic data.
To priporočilo temelji na farmakodinamičnih in farmakokinetičnih podatkih.
30 days
30 dni
A target aPTT of 50-70 seconds was recommended.
Priporočeni ciljni aPTČ je bil od 50 do 70 sekund.
Very rarely, bleeding has become severe and even fatal.
V zelo redkih primerih so bile krvavitve hude in celo smrtne.
Thus, changes in laboratory parameters associated with bleeding (e.g. bleeding time) are common and expected.
Spremembe laboratorijskih parametrov, povezanih s strjevanjem krvi (npr. časa krvavitve), so pogoste in pričakovane.
Please refer to the Normosol R Summary of Product Characteristics for details on its composition.
Prosimo, glejte Povzetek glavnih značilnosti zdravila Normosol R za podrobnosti o njegovi sestavi.
No formal pharmacokinetic interaction studies have been conducted.
Formalnih študij farmakokinetičnih interakcij ni bilo.
Safety measures to prevent this from happening include blood tests and careful checking by the healthcare professionals taking care of you.
Med varnostne ukrepe za preprečevanje krvavitev sodijo krvne preiskave in skrbno spremljanje bolnika s strani zdravstvenega osebja, ki skrbi zanj.
Prolongation of bleeding time
Podaljšanje časa krvavitve
- sudden, severe allergic reaction.
- nenadna, huda alergijska reakcija.
Warfarin and dipyridamole
Varfarin in dipiridamol
The extent of eptifibatide binding to human plasma protein is about 25 %.
Delež vezave eptifibatida na plazemske proteine pri človeku je približno 25 %.
This leaflet was last revised in <{MM/YYYY}>.
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}>
In the absence of compatibility studies, Eptifibatide Accord must not be mixed with other medicinal products except those mentioned in 6.6.
Zaradi pomanjkanja študij kompatibilnosti zdravila Eptifibatide Accord ne smemo mešati z drugimi zdravili, razen s tistimi, ki so našteta v poglavju 6.6.
Heparin administration
Uporaba heparina
The decision to use platelet transfusions should be based upon clinical judgment on an individual basis.
Odločitev za dajanje transfuzije trombocitov mora temeljiti na klinični presoji posameznega primera.
Discontinue unfractionated heparin.
Ukinite uporabo nefrakcioniranega heparina.
0.034a a: Pearson's chi-square test of difference between placebo and eptifibatide.
0,034a a: Pearsonov test hi-kvadrat za ugotavljanje statistične značilnosti razlike med placebom in eptifibatidom.
Note that causality has not been determined for all adverse reactions.
Opozorilo: vzročnost ni bila ugotovljena za vse neželene učinke.
< 1/1000); very rare (< 1/10,000); not known (cannot be estimated from available data).
< 1/1.000), zelo redki (< 1/10.000); neznani (ni mogoče oceniti iz razpoložljivih podatkov).
The available clinical evidence cannot however confirm that this dose modification results in a preserved benefit (see section 5.1).
Vendar klinični dokazi, ki so na voljo, ne morejo potrditi, da takšna prilagoditev odmerka ohrani koristi (glejte poglavje 5.1).
The carcinogenic potential of eptifibatide has not been evaluated in long-term studies.
Kancerogenosti eptifibatida niso ovrednotili z dolgoročnimi študijami.
If you have kidney disease, the infusion dose may be reduced to 1 microgram/kg/minute.
Če imate bolezen ledvic, se odmerek lahko zmanjša na 1 mikrogram/kg/minuto.
Other events that may occur in patients, who require this type of treatment, include those that are related to the condition you are having treated, such as rapid or irregular heartbeat, low blood pressure, shock or cardiac arrest.
Drugi neželeni učinki, ki se lahko pojavijo pri bolnikih, ki potrebujejo tovrstno zdravljenje, vključujejo tiste, ki so povezani z zdravstvenim stanjem, ki se zdravi, npr. hiter ali nepravilen srčni utrip, nizek krvni tlak, šok ali srčni zastoj.
Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Študije na živalih ne zadostujejo za oceno vpliva na nosečnost, razvoj zarodka/plodu, porod ali postnatalni razvoj (glejte poglavje 5.3).
− if you are allergic to eptifibatide or any of the other ingredients of this medicine (listed in section
− če ste alergični na eptifibatid ali katerokoli drugo sestavino tega zdravila (navedeno v poglavju
The clinical relevance of such enzymatic MIs is still controversial.
Klinični pomen tako opredeljenega encimskega miokardnega infarkta je še vedno sporen.
You must also be given doses of aspirin and heparin (if not contraindicated in your case).
Dobiti morate tudi odmerke acetilsalicilne kisline in heparina (če ta ni kontraindiciran pri vas).
- anaemia (decreased number of red blood cells).
- anemija (zmanjšano število rdečih krvnih celic).
The vast majority of patients received acetylsalicylic acid (75-325 mg once daily).
Velika večina bolnikov je prejemala acetilsalicilno kislino (75 do 325 mg enkrat na dan).
Use in patients with more severe renal impairment is contraindicated (see section 4.3).
Uporaba pri bolnikih s hujšo ledvično okvaro je kontraindicirana (glejte poglavje 4.3).
To avoid the possibility of interactions with other medicines please tell your doctor or hospital pharmacist or nurse if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription.
Da bi se izognili morebitnemu medsebojnemu delovanju z drugimi zdravili, obvestite svojega zdravnika, bolnišničnega farmacevta ali medicinsko sestro, če jemljete ali ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Eptifibatide -treated patients who had a prothrombin time (PT) > 14.5 seconds and received warfarin concomitantly did not appear to be at an increased risk of bleeding.
Tudi pri z eptifibatidom zdravljenih bolnikih, ki so imeli protrombinski čas (PČ) > 14,5 sekund in so sočasno prejemali varfarin, ni kazalo, da bi bili bolj ogroženi zaradi krvavitev.
There are no adequate data from the use of eptifibatide in pregnant women.
Ni zadostnih podatkov o uporabi eptifibatida pri nosečnicah.
− if you have been treated with another medicine of the same type as Eptifibatide Accord.
− če ste bili zdravljeni z drugim zdravilom iste vrste, kot je Eptifibatide Accord.
Results on the primary endpoint were principally attributed to the occurrence of myocardial infarction.
Izsledki za primarni končni cilj so bili pripisani predvsem pojavu miokardnega infarkta.
It should be administered by specialist physicians experienced in the management of acute coronary syndromes.
Dajati ga morajo specialisti z izkušnjami na področju zdravljenja akutnih koronarnih sindromov.
The 180/1.3 arm was stopped after an interim analysis, as prespecified in the protocol, when the two active-treatment arms appeared to have a similar incidence of bleeding.
Krak 180/1,3 te študije so ustavili po vmesni analizi, kot je bilo vnaprej določeno v protokolu, ker je kazalo, da je incidenca krvavitev v obeh krakih z aktivnim zdravljenjem podobna.
These are absolute reporting frequencies without taking into account placebo rates.
To so absolutne zabeležene pogostnosti, neupoštevaje deleže pri placebu.
In ESPRIT, bleeding events were reported at 48 hours, and non-bleeding events were reported at 30 days.
V študiji ESPRIT so krvavitvene dogodke zabeležili po 48 urah, nekrvavitvene pa po 30 dneh.
Potentially, an overdose of eptifibatide could result in bleeding.
Preveliko odmerjanje eptifibatida bi lahko povzročilo krvavitve.
− Eptifibatide Accord is not intended for use in children or adolescents less than 18 years of age.
− Zdravilo Eptifibatide Accord ni namenjeno za uporabo pri otrocih in mladostnikih do 18. leta starosti.
Other potential bleeding sites such as central and peripheral nervous system and retroperitoneal sites, must be carefully considered too.
Skrbno preglejte tudi druga možna mesta krvavitev, npr. osrednje in periferno živčevje ter retroperitonealni prostor.
Specifically, no patients experienced an intracranial bleed.
Noben bolnik ni imel intrakranialne krvavitve.
Unlike the approved posology in the EU, all patients in this trial were administered a double bolus before the infusion (see section 5.1).
V nasprotju z odmerjanjem, odobrenim v EU, so vsi bolniki v tej študiji pred infundiranjem dobili dvojni bolus (glejte poglavje 5.1).
− if you had a major operation or severe injury during the past 6 weeks.
− če ste imeli v zadnjih 6 tednih večjo operacijo ali hudo poškodbo;
The reduction in the incidence of endpoint events in patients receiving eptifibatide appeared early during treatment (within the first 72-96 hours) and this reduction was maintained through 6 months, without any significant effect on mortality.
Zmanjšanje incidence pojavov končnega cilja pri bolnikih, ki so prejemali eptifibatid, se je pojavilo že zgodaj med zdravljenjem (v roku prvih 72 do 96 ur) in je bilo prisotno vseh 6 mesecev, brez bistvenega učinka na umrljivost.
Administration of eptifibatide by intravenous bolus and infusion causes up to a 5-fold increase in bleeding time.
Uporaba eptifibatida v intravenskem bolusu in infuziji povzroči do 5-kratno podaljšanje časa krvavitve.
When administered alone, eptifibatide has no measurable effect on prothrombin time (PT) or activated partial thromboplastin time (aPTT).
Eptifibatid, uporabljen sam, nima merljivega učinka na protrombinski čas (PČ) ali aktivirani parcialni tromboplastinski čas (aPTČ).